Breaking News, Collaborations & Alliances

Junshi, Lilly to Develop Antibody Therapies for COVID-19

Multiple neutralizing antibodies have been engineered, with the lead asset poised to enter clinical testing in the second quarter

By: Contract Pharma

Contract Pharma Staff

Junshi Biosciences and Eli Lilly have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus.   At the beginning of the COVID-19 outbreak, Junshi Biosciences—a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel therapies—launched one of the industry’s first R&D efforts aimed at discovering therapies to combat COVID-1...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters